Abstract
Cultured cell lines derived from malignant Epstein-Barr virus (EBV)-negative B cells, and representative of the more common types of naturally occurring non-Hodgkin lymphomas and related leukemias, were found to be sensitive to lysis by human natural killer (NK) cells. The observed lysis of such cell lines was mediated by a population of interferon-augmentable, FcR-positive, non-adherent lymphoid cells, which were also able to kill the "standard" NK targets K562 and Molt-4. When the NK susceptibility of the neoplastic, EBV-negative B cells was compared to that of diploid, EBV-carrying, non-neoplastic B lymphoblastoid cell lines (BLCLs) and of the "standard" NK target K562, several distinct patterns were observed. The killing of the neoplastic B cell lines was significantly less than that of K562, but significantly greater than that of the EBV-derived BLCLs of non-neoplastic origin. An additional finding was a similar NK susceptibility profile for the neoplastic, true histiocytic cell line U-937 (i.e., K562 greater than U937 greater than BLCLs). Furthermore, all cell lines, with the exception of the BLCLs, could effectively compete for the observed killing in cold target inhibition assays. The implications of these findings are ...Continue Reading
References
Jan 1, 1978·Journal of the National Cancer Institute·J W ParkerR J Lukes
Jan 18, 1979·Nature·R R HerbermanG D Bonnard
Jan 1, 1979·Cellular Immunology·I HeronK Berg
Sep 15, 1979·Cellular Immunology·R A MillerH S Kaplan
Feb 15, 1975·International Journal of Cancer. Journal International Du Cancer·K Nilsson, J Pontén
Apr 1, 1975·Proceedings of the National Academy of Sciences of the United States of America·E Svedmyr, M Jondal
Jan 1, 1975·British Journal of Cancer·R D BarnesJ Holliday
Dec 4, 1975·The New England Journal of Medicine·I RoystonE Perlin
May 15, 1976·International Journal of Cancer. Journal International Du Cancer·C Sundström, K Nilsson
Jun 1, 1976·Journal of Virology·G MillerJ Pagano
Jul 15, 1979·International Journal of Cancer. Journal International Du Cancer·B GiovanellaJ S Stehlin
Apr 7, 1977·Nature·A OnoH S Koren
Aug 1, 1977·Cellular Immunology·T BakacsE Klein
Sep 1, 1977·Cellular Immunology·D M CallewaertJ J Lightbody
Mar 2, 1978·Nature·M JondalS Targan
Jan 1, 1978·Advances in Cancer Research·R B Herberman, H T Holden
Jan 1, 1979·Scandinavian Journal of Immunology·O Sjöberg, M Inganäs
Jan 1, 1979·Scandinavian Journal of Immunology·E SakselaK Cantell
Jun 29, 1978·Nature·M GidlundI Gresser
Dec 15, 1977·Nature·G TrinchieriB B Knowles
May 1, 1978·The Journal of Experimental Medicine·G Trinchieri, D Santoli
Jan 1, 1979·Immunological Reviews·R B HerbermanP Puccetti
Jul 15, 1977·International Journal of Cancer. Journal International Du Cancer·O HallerH Wigzell
Jun 1, 1976·Scandinavian Journal of Immunology·H Wigzell
Jun 15, 1974·International Journal of Cancer. Journal International Du Cancer·K Nilsson, C Sundström
Jan 1, 1973·Proceedings of the National Academy of Sciences of the United States of America·G Miller, M Lipman
Nov 15, 1971·International Journal of Cancer. Journal International Du Cancer·K Nilsson
Mar 1, 1966·Journal of Invertebrate Pathology·G MatzJ P Ebel
Mar 1, 1980·The Journal of Experimental Medicine·B BlazarG Klein
Oct 1, 1980·The Journal of Clinical Investigation·H D Kay, D A Horwitz
Aug 27, 1981·Nature·M GidlundK Nilsson
May 29, 1980·Nature·P SternH Wigzell
Citations
Mar 1, 1988·Blood Reviews·P G Hogan, A Basten
Jan 15, 1982·International Journal of Cancer. Journal International Du Cancer·P K PattengaleH Wigzell
Dec 1, 1982·British Journal of Haematology·T H TöttermanH Wigzell
Dec 17, 2014·Cancer Letters·Lakshmi Narendra BodduluruChandra Shaker Sriram
Jul 21, 1983·Nature·D Banerjee, R F Thibert
May 27, 2006·International Immunology·Kevin S GorskiSefik S Alkan
Dec 25, 2019·Cold Spring Harbor Perspectives in Medicine·Hugo R Rosen, Lucy Golden-Mason
Apr 1, 1991·European Journal of Haematology·H Jernberg-WiklundK Nilsson
Oct 1, 1983·Hematological Oncology·K NilssonL Zech
Oct 15, 1982·Virology·E E HendersonR J Suhadolnik